Karo Pharma completes the acquisition of the brand portfolio from Teva Pharmaceuticals
Karo Pharma Aktiebolag (“Karo”) today announces that the acquisition of the European OTC brand portfolio from Teva Pharmaceuticals (Teva) for 84 MEUR, which was signed and announced on 3 February 2021, has been completed. The transaction transfers ownership of the brand portfolio, comprised of Flux[®], Decubal[®], Lactocare[®], Apobase[®], Dailycare[®] and Fludent[®] from Teva to Karo. Karo and Teva have had a close and seamless collaboration since the signing of the agreement leading up to the closing according to plan. For further information, please contact:Christoffer